Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-07-24

AUTHORS

Nicholas D. Klemen, Melinda Wang, Paul L. Feingold, Kirsten Cooper, Sabrina N. Pavri, Dale Han, Frank C. Detterbeck, Daniel J. Boffa, Sajid A. Khan, Kelly Olino, James Clune, Stephan Ariyan, Ronald R. Salem, Sarah A. Weiss, Harriet M. Kluger, Mario Sznol, Charles Cha

ABSTRACT

BackgroundCheckpoint inhibitors (CPI) have revolutionized the treatment of metastatic melanoma, but most patients treated with CPI eventually develop progressive disease. Local therapy including surgery, ablation or stereotactic body radiotherapy (SBRT) may be useful to manage limited progression, but criteria for patient selection have not been established. Previous work has suggested progression-free survival (PFS) after local therapy is associated with patterns of immunotherapy failure, but this has not been studied in patients treated with CPI.MethodsWe analyzed clinical data from patients with metastatic melanoma who were treated with antibodies against CTLA-4, PD-1 or PD-L1, either as single-agent or combination therapy, and identified those who had disease progression in 1 to 3 sites managed with local therapy. Patterns of CPI failure were designated by independent radiological review as growth of established metastases or appearance of new metastases. Local therapy for diagnosis, palliation or CNS metastases was excluded.ResultsFour hundred twenty-eight patients with metastatic melanoma received treatment with CPI from 2007 to 2018. Seventy-seven have ongoing complete responses while 69 died within 6 months of starting CPI; of the remaining 282 patients, 52 (18%) were treated with local therapy meeting our inclusion criteria. Local therapy to achieve no evidence of disease (NED) was associated with three-year progression-free survival (PFS) of 31% and five-year disease-specific survival (DSS) of 60%. Stratified by patterns of failure, patients with progression in established tumors had three-year PFS of 70%, while those with new metastases had three-year PFS of 6% (P = 0.001). Five-year DSS after local therapy was 93% versus 31%, respectively (P = 0.046).ConclusionsLocal therapy for oligoprogression after CPI can result in durable PFS in selected patients. We observed that patterns of failure seen during or after CPI treatment are strongly associated with PFS after local therapy, and may represent a useful criterion for patient selection. This experience suggests there may be an increased role for local therapy in patients being treated with immunotherapy. More... »

PAGES

196

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s40425-019-0672-3

DOI

http://dx.doi.org/10.1186/s40425-019-0672-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1119788797

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/31340861


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Immunological", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "B7-H1 Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "CTLA-4 Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Central Nervous System Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Melanoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Patient Selection", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Programmed Cell Death 1 Receptor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Progression-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Failure", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Section of Surgical Oncology, Yale School of Medicine, 20 Park Street, 06519, New Haven, CT, USA", 
          "id": "http://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Section of Surgical Oncology, Yale School of Medicine, 20 Park Street, 06519, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Klemen", 
        "givenName": "Nicholas D.", 
        "id": "sg:person.01040055605.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040055605.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Section of Surgical Oncology, Yale School of Medicine, 20 Park Street, 06519, New Haven, CT, USA", 
          "id": "http://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Section of Surgical Oncology, Yale School of Medicine, 20 Park Street, 06519, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Melinda", 
        "id": "sg:person.014455567337.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014455567337.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Section of Surgical Oncology, Yale School of Medicine, 20 Park Street, 06519, New Haven, CT, USA", 
          "id": "http://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Section of Surgical Oncology, Yale School of Medicine, 20 Park Street, 06519, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Feingold", 
        "givenName": "Paul L.", 
        "id": "sg:person.01166771111.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166771111.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiology, Yale School of Medicine, New Haven, CT, USA", 
          "id": "http://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Department of Radiology, Yale School of Medicine, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cooper", 
        "givenName": "Kirsten", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Orlando Health Aesthetic and Reconstructive Surgery Institute, Orlando, FL, USA", 
          "id": "http://www.grid.ac/institutes/grid.416912.9", 
          "name": [
            "Orlando Health Aesthetic and Reconstructive Surgery Institute, Orlando, FL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pavri", 
        "givenName": "Sabrina N.", 
        "id": "sg:person.01317277074.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317277074.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Surgical Oncology, Oregon Health and Science University, Portland, OR, USA", 
          "id": "http://www.grid.ac/institutes/grid.5288.7", 
          "name": [
            "Division of Surgical Oncology, Oregon Health and Science University, Portland, OR, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Han", 
        "givenName": "Dale", 
        "id": "sg:person.0607026044.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607026044.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Section of Thoracic Surgery, Yale School of Medicine, New Haven, CT, USA", 
          "id": "http://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Section of Thoracic Surgery, Yale School of Medicine, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Detterbeck", 
        "givenName": "Frank C.", 
        "id": "sg:person.01156030507.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156030507.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Section of Thoracic Surgery, Yale School of Medicine, New Haven, CT, USA", 
          "id": "http://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Section of Thoracic Surgery, Yale School of Medicine, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Boffa", 
        "givenName": "Daniel J.", 
        "id": "sg:person.01016352134.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016352134.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Section of Surgical Oncology, Yale School of Medicine, 20 Park Street, 06519, New Haven, CT, USA", 
          "id": "http://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Section of Surgical Oncology, Yale School of Medicine, 20 Park Street, 06519, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Khan", 
        "givenName": "Sajid A.", 
        "id": "sg:person.012613314147.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012613314147.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Section of Surgical Oncology, Yale School of Medicine, 20 Park Street, 06519, New Haven, CT, USA", 
          "id": "http://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Section of Surgical Oncology, Yale School of Medicine, 20 Park Street, 06519, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Olino", 
        "givenName": "Kelly", 
        "id": "sg:person.01127457063.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127457063.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Section of Plastic and Reconstructive Surgery, Yale School of Medicine, New Haven, CT, USA", 
          "id": "http://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Section of Plastic and Reconstructive Surgery, Yale School of Medicine, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Clune", 
        "givenName": "James", 
        "id": "sg:person.01076636275.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01076636275.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Section of Plastic and Reconstructive Surgery, Yale School of Medicine, New Haven, CT, USA", 
          "id": "http://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Section of Plastic and Reconstructive Surgery, Yale School of Medicine, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ariyan", 
        "givenName": "Stephan", 
        "id": "sg:person.014265505777.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014265505777.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Section of Surgical Oncology, Yale School of Medicine, 20 Park Street, 06519, New Haven, CT, USA", 
          "id": "http://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Section of Surgical Oncology, Yale School of Medicine, 20 Park Street, 06519, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Salem", 
        "givenName": "Ronald R.", 
        "id": "sg:person.0616726362.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0616726362.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA", 
          "id": "http://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Weiss", 
        "givenName": "Sarah A.", 
        "id": "sg:person.012276320555.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012276320555.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA", 
          "id": "http://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kluger", 
        "givenName": "Harriet M.", 
        "id": "sg:person.01336750727.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336750727.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA", 
          "id": "http://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sznol", 
        "givenName": "Mario", 
        "id": "sg:person.0706626451.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706626451.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Section of Surgical Oncology, Yale School of Medicine, 20 Park Street, 06519, New Haven, CT, USA", 
          "id": "http://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Section of Surgical Oncology, Yale School of Medicine, 20 Park Street, 06519, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cha", 
        "givenName": "Charles", 
        "id": "sg:person.01117026632.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117026632.29"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1245/s10434-013-2999-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013136445", 
          "https://doi.org/10.1245/s10434-013-2999-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ng.2359", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021618497", 
          "https://doi.org/10.1038/ng.2359"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1245/s10434-012-2398-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036889506", 
          "https://doi.org/10.1245/s10434-012-2398-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1245/s10434-017-6072-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092156332", 
          "https://doi.org/10.1245/s10434-017-6072-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1245/s10434-016-5537-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026233646", 
          "https://doi.org/10.1245/s10434-016-5537-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1245/s10434-013-3089-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049896977", 
          "https://doi.org/10.1245/s10434-013-3089-0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-07-24", 
    "datePublishedReg": "2019-07-24", 
    "description": "BackgroundCheckpoint inhibitors (CPI) have revolutionized the treatment of metastatic melanoma, but most patients treated with CPI eventually develop progressive disease. Local therapy including surgery, ablation or stereotactic body radiotherapy (SBRT) may be useful to manage limited progression, but criteria for patient selection have not been established. Previous work has suggested progression-free survival (PFS) after local therapy is associated with patterns of immunotherapy failure, but this has not been studied in patients treated with CPI.MethodsWe analyzed clinical data from patients with metastatic melanoma who were treated with antibodies against CTLA-4, PD-1 or PD-L1, either as single-agent or combination therapy, and identified those who had disease progression in 1 to 3 sites managed with local therapy. Patterns of CPI failure were designated by independent radiological review as growth of established metastases or appearance of new metastases. Local therapy for diagnosis, palliation or CNS metastases was excluded.ResultsFour hundred twenty-eight patients with metastatic melanoma received treatment with CPI from 2007 to 2018. Seventy-seven have ongoing complete responses while 69 died within 6\u2009months of starting CPI; of the remaining 282 patients, 52 (18%) were treated with local therapy meeting our inclusion criteria. Local therapy to achieve no evidence of disease (NED) was associated with three-year progression-free survival (PFS) of 31% and five-year disease-specific survival (DSS) of 60%. Stratified by patterns of failure, patients with progression in established tumors had three-year PFS of 70%, while those with new metastases had three-year PFS of 6% (P\u2009=\u20090.001). Five-year DSS after local therapy was 93% versus 31%, respectively (P\u2009=\u20090.046).ConclusionsLocal therapy for oligoprogression after CPI can result in durable PFS in selected patients. We observed that patterns of failure seen during or after CPI treatment are strongly associated with PFS after local therapy, and may represent a useful criterion for patient selection. This experience suggests there may be an increased role for local therapy in patients being treated with immunotherapy.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s40425-019-0672-3", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.7439502", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.5475983", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1049249", 
        "issn": [
          "2051-1426"
        ], 
        "name": "Journal for ImmunoTherapy of Cancer", 
        "publisher": "BMJ", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "7"
      }
    ], 
    "keywords": [
      "Three-year progression-free survival", 
      "progression-free survival", 
      "disease-specific survival", 
      "Five-year disease-specific survival", 
      "patterns of failure", 
      "durable progression-free survival", 
      "local therapy", 
      "stereotactic body radiotherapy", 
      "metastatic melanoma", 
      "patient selection", 
      "new metastases", 
      "independent radiological review", 
      "ResultsFour hundred twenty", 
      "ongoing complete response", 
      "evidence of disease", 
      "immunotherapy failure", 
      "CNS metastasis", 
      "CPI treatment", 
      "checkpoint inhibitors", 
      "most patients", 
      "progressive disease", 
      "radiological review", 
      "PD-1", 
      "PD-L1", 
      "complete response", 
      "body radiotherapy", 
      "combination therapy", 
      "CTLA-4", 
      "disease progression", 
      "clinical data", 
      "hundred twenty", 
      "inclusion criteria", 
      "limited progression", 
      "patients", 
      "therapy", 
      "metastasis", 
      "melanoma", 
      "progression", 
      "survival", 
      "immunotherapy", 
      "treatment", 
      "disease", 
      "failure", 
      "inhibitors", 
      "oligoprogression", 
      "palliation", 
      "surgery", 
      "radiotherapy", 
      "tumors", 
      "MethodsWe", 
      "diagnosis", 
      "criteria", 
      "antibodies", 
      "months", 
      "useful criterion", 
      "ablation", 
      "patterns", 
      "twenties", 
      "review", 
      "response", 
      "evidence", 
      "role", 
      "appearance", 
      "experience", 
      "data", 
      "sites", 
      "CPI", 
      "selection", 
      "growth", 
      "CPI failures", 
      "previous work", 
      "work"
    ], 
    "name": "Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma", 
    "pagination": "196", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1119788797"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s40425-019-0672-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "31340861"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s40425-019-0672-3", 
      "https://app.dimensions.ai/details/publication/pub.1119788797"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:46", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_834.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s40425-019-0672-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0672-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0672-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0672-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0672-3'


 

This table displays all metadata directly associated to this object as RDF triples.

349 TRIPLES      21 PREDICATES      119 URIs      105 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s40425-019-0672-3 schema:about N0869627061cc4a299a29949c544e7d64
2 N0a78a60a7f304fe88c44b2e42de8d789
3 N47061c6a1d744f1d911f793475219e0a
4 N59ce69d7e3da44f384c23236fd588d9e
5 N67c108a5ffdf4f01ab89ac098eb45a2b
6 N6cd05994fd89463e8eb247a228aa1ede
7 N710fd6ee05e0498683b3bc1394c947b1
8 N768db5f913e34a608d949207b33c97eb
9 Na155659ca34341459f3507020bd4e18c
10 Na24147960d774c7abd32e17b45167b81
11 Naaf624fbb8634a8ba5506541456b1d36
12 Nbc29fb826e1b43dc91b1166dead8e653
13 Nbf43d934f9de4cebb40d6dd643900f92
14 Nde74e837584c434ead4271d07d18140f
15 Ndf299480d7544e6e890b759e67ef5f84
16 Nef8d1abd1c8f4f1fad29130cd66c72d9
17 anzsrc-for:11
18 anzsrc-for:1112
19 schema:author N3590b19c432c42d187c2fc47424cb3ac
20 schema:citation sg:pub.10.1038/ng.2359
21 sg:pub.10.1245/s10434-012-2398-z
22 sg:pub.10.1245/s10434-013-2999-1
23 sg:pub.10.1245/s10434-013-3089-0
24 sg:pub.10.1245/s10434-016-5537-0
25 sg:pub.10.1245/s10434-017-6072-3
26 schema:datePublished 2019-07-24
27 schema:datePublishedReg 2019-07-24
28 schema:description BackgroundCheckpoint inhibitors (CPI) have revolutionized the treatment of metastatic melanoma, but most patients treated with CPI eventually develop progressive disease. Local therapy including surgery, ablation or stereotactic body radiotherapy (SBRT) may be useful to manage limited progression, but criteria for patient selection have not been established. Previous work has suggested progression-free survival (PFS) after local therapy is associated with patterns of immunotherapy failure, but this has not been studied in patients treated with CPI.MethodsWe analyzed clinical data from patients with metastatic melanoma who were treated with antibodies against CTLA-4, PD-1 or PD-L1, either as single-agent or combination therapy, and identified those who had disease progression in 1 to 3 sites managed with local therapy. Patterns of CPI failure were designated by independent radiological review as growth of established metastases or appearance of new metastases. Local therapy for diagnosis, palliation or CNS metastases was excluded.ResultsFour hundred twenty-eight patients with metastatic melanoma received treatment with CPI from 2007 to 2018. Seventy-seven have ongoing complete responses while 69 died within 6 months of starting CPI; of the remaining 282 patients, 52 (18%) were treated with local therapy meeting our inclusion criteria. Local therapy to achieve no evidence of disease (NED) was associated with three-year progression-free survival (PFS) of 31% and five-year disease-specific survival (DSS) of 60%. Stratified by patterns of failure, patients with progression in established tumors had three-year PFS of 70%, while those with new metastases had three-year PFS of 6% (P = 0.001). Five-year DSS after local therapy was 93% versus 31%, respectively (P = 0.046).ConclusionsLocal therapy for oligoprogression after CPI can result in durable PFS in selected patients. We observed that patterns of failure seen during or after CPI treatment are strongly associated with PFS after local therapy, and may represent a useful criterion for patient selection. This experience suggests there may be an increased role for local therapy in patients being treated with immunotherapy.
29 schema:genre article
30 schema:isAccessibleForFree true
31 schema:isPartOf N26710bddfee8445f8fbd6e67d2bd7391
32 N46f5ee1b2e134a19a4668e32277dc74f
33 sg:journal.1049249
34 schema:keywords CNS metastasis
35 CPI
36 CPI failures
37 CPI treatment
38 CTLA-4
39 Five-year disease-specific survival
40 MethodsWe
41 PD-1
42 PD-L1
43 ResultsFour hundred twenty
44 Three-year progression-free survival
45 ablation
46 antibodies
47 appearance
48 body radiotherapy
49 checkpoint inhibitors
50 clinical data
51 combination therapy
52 complete response
53 criteria
54 data
55 diagnosis
56 disease
57 disease progression
58 disease-specific survival
59 durable progression-free survival
60 evidence
61 evidence of disease
62 experience
63 failure
64 growth
65 hundred twenty
66 immunotherapy
67 immunotherapy failure
68 inclusion criteria
69 independent radiological review
70 inhibitors
71 limited progression
72 local therapy
73 melanoma
74 metastasis
75 metastatic melanoma
76 months
77 most patients
78 new metastases
79 oligoprogression
80 ongoing complete response
81 palliation
82 patient selection
83 patients
84 patterns
85 patterns of failure
86 previous work
87 progression
88 progression-free survival
89 progressive disease
90 radiological review
91 radiotherapy
92 response
93 review
94 role
95 selection
96 sites
97 stereotactic body radiotherapy
98 surgery
99 survival
100 therapy
101 treatment
102 tumors
103 twenties
104 useful criterion
105 work
106 schema:name Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma
107 schema:pagination 196
108 schema:productId N4ba821600a8f4e0ca11de3191886f17c
109 N81c1a19f56a34f3891aabf291a263248
110 Nd4bbd30b56654470a2bcbcd15f585ee3
111 schema:sameAs https://app.dimensions.ai/details/publication/pub.1119788797
112 https://doi.org/10.1186/s40425-019-0672-3
113 schema:sdDatePublished 2022-10-01T06:46
114 schema:sdLicense https://scigraph.springernature.com/explorer/license/
115 schema:sdPublisher Nd25cc3b217c14f37b3e543313bed1c48
116 schema:url https://doi.org/10.1186/s40425-019-0672-3
117 sgo:license sg:explorer/license/
118 sgo:sdDataset articles
119 rdf:type schema:ScholarlyArticle
120 N059b335e990d4461a22e8e184bf24f0a schema:affiliation grid-institutes:grid.47100.32
121 schema:familyName Cooper
122 schema:givenName Kirsten
123 rdf:type schema:Person
124 N0869627061cc4a299a29949c544e7d64 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Male
126 rdf:type schema:DefinedTerm
127 N0a78a60a7f304fe88c44b2e42de8d789 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Progression-Free Survival
129 rdf:type schema:DefinedTerm
130 N13b4f85db9424e59a9edf33494694afa rdf:first sg:person.01016352134.46
131 rdf:rest Nc3db7ff3a43541ab8a49b80b339c2bd7
132 N1bca0477837d4a948080b00db09f4637 rdf:first sg:person.01076636275.12
133 rdf:rest N9eb1b48595a74f919e77579d6cfc88ee
134 N26710bddfee8445f8fbd6e67d2bd7391 schema:issueNumber 1
135 rdf:type schema:PublicationIssue
136 N2ace423d0f9a442cb4736287b7205ab4 rdf:first sg:person.0607026044.65
137 rdf:rest Nf64062ecae314735ac71af88e969ec0e
138 N2d0b27c40f044c678e4d9a2bafcc8a05 rdf:first sg:person.014455567337.71
139 rdf:rest Nc87ec95225fd4065aa2e5d5d6673b728
140 N3590b19c432c42d187c2fc47424cb3ac rdf:first sg:person.01040055605.46
141 rdf:rest N2d0b27c40f044c678e4d9a2bafcc8a05
142 N46f5ee1b2e134a19a4668e32277dc74f schema:volumeNumber 7
143 rdf:type schema:PublicationVolume
144 N47061c6a1d744f1d911f793475219e0a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Antineoplastic Combined Chemotherapy Protocols
146 rdf:type schema:DefinedTerm
147 N47340d4d8acf470e8bf71ed48b116120 rdf:first sg:person.01317277074.82
148 rdf:rest N2ace423d0f9a442cb4736287b7205ab4
149 N4ba821600a8f4e0ca11de3191886f17c schema:name pubmed_id
150 schema:value 31340861
151 rdf:type schema:PropertyValue
152 N59ce69d7e3da44f384c23236fd588d9e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Patient Selection
154 rdf:type schema:DefinedTerm
155 N62848f9b43174d49abf744747e0b52f8 rdf:first sg:person.0706626451.72
156 rdf:rest Ne545841010e34b93b5dab8dd8b76059b
157 N67c108a5ffdf4f01ab89ac098eb45a2b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Antineoplastic Agents, Immunological
159 rdf:type schema:DefinedTerm
160 N6cd05994fd89463e8eb247a228aa1ede schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Central Nervous System Neoplasms
162 rdf:type schema:DefinedTerm
163 N710fd6ee05e0498683b3bc1394c947b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Melanoma
165 rdf:type schema:DefinedTerm
166 N768db5f913e34a608d949207b33c97eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Middle Aged
168 rdf:type schema:DefinedTerm
169 N81c1a19f56a34f3891aabf291a263248 schema:name dimensions_id
170 schema:value pub.1119788797
171 rdf:type schema:PropertyValue
172 N8499ed38a6714d30823f5e204f034ac9 rdf:first sg:person.0616726362.23
173 rdf:rest Nd3e2eb68f549448d9aab6fc81e7114fa
174 N8a1b1f1cb69c4ba8923538d69dc8458a rdf:first sg:person.01127457063.99
175 rdf:rest N1bca0477837d4a948080b00db09f4637
176 N9eb1b48595a74f919e77579d6cfc88ee rdf:first sg:person.014265505777.28
177 rdf:rest N8499ed38a6714d30823f5e204f034ac9
178 Na155659ca34341459f3507020bd4e18c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name B7-H1 Antigen
180 rdf:type schema:DefinedTerm
181 Na24147960d774c7abd32e17b45167b81 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Aged
183 rdf:type schema:DefinedTerm
184 Naaf624fbb8634a8ba5506541456b1d36 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Treatment Failure
186 rdf:type schema:DefinedTerm
187 Nb251e7ae157049f7a545d78b4c8c5bcb rdf:first sg:person.01336750727.45
188 rdf:rest N62848f9b43174d49abf744747e0b52f8
189 Nbc29fb826e1b43dc91b1166dead8e653 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Humans
191 rdf:type schema:DefinedTerm
192 Nbf43d934f9de4cebb40d6dd643900f92 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Female
194 rdf:type schema:DefinedTerm
195 Nc3db7ff3a43541ab8a49b80b339c2bd7 rdf:first sg:person.012613314147.62
196 rdf:rest N8a1b1f1cb69c4ba8923538d69dc8458a
197 Nc87ec95225fd4065aa2e5d5d6673b728 rdf:first sg:person.01166771111.54
198 rdf:rest Nfbf45f42e77941ce9d793642ae333ad5
199 Nd25cc3b217c14f37b3e543313bed1c48 schema:name Springer Nature - SN SciGraph project
200 rdf:type schema:Organization
201 Nd3e2eb68f549448d9aab6fc81e7114fa rdf:first sg:person.012276320555.98
202 rdf:rest Nb251e7ae157049f7a545d78b4c8c5bcb
203 Nd4bbd30b56654470a2bcbcd15f585ee3 schema:name doi
204 schema:value 10.1186/s40425-019-0672-3
205 rdf:type schema:PropertyValue
206 Nde74e837584c434ead4271d07d18140f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Programmed Cell Death 1 Receptor
208 rdf:type schema:DefinedTerm
209 Ndf299480d7544e6e890b759e67ef5f84 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
210 schema:name CTLA-4 Antigen
211 rdf:type schema:DefinedTerm
212 Ne545841010e34b93b5dab8dd8b76059b rdf:first sg:person.01117026632.29
213 rdf:rest rdf:nil
214 Nef8d1abd1c8f4f1fad29130cd66c72d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
215 schema:name Immunotherapy
216 rdf:type schema:DefinedTerm
217 Nf64062ecae314735ac71af88e969ec0e rdf:first sg:person.01156030507.16
218 rdf:rest N13b4f85db9424e59a9edf33494694afa
219 Nfbf45f42e77941ce9d793642ae333ad5 rdf:first N059b335e990d4461a22e8e184bf24f0a
220 rdf:rest N47340d4d8acf470e8bf71ed48b116120
221 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
222 schema:name Medical and Health Sciences
223 rdf:type schema:DefinedTerm
224 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
225 schema:name Oncology and Carcinogenesis
226 rdf:type schema:DefinedTerm
227 sg:grant.5475983 http://pending.schema.org/fundedItem sg:pub.10.1186/s40425-019-0672-3
228 rdf:type schema:MonetaryGrant
229 sg:grant.7439502 http://pending.schema.org/fundedItem sg:pub.10.1186/s40425-019-0672-3
230 rdf:type schema:MonetaryGrant
231 sg:journal.1049249 schema:issn 2051-1426
232 schema:name Journal for ImmunoTherapy of Cancer
233 schema:publisher BMJ
234 rdf:type schema:Periodical
235 sg:person.01016352134.46 schema:affiliation grid-institutes:grid.47100.32
236 schema:familyName Boffa
237 schema:givenName Daniel J.
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016352134.46
239 rdf:type schema:Person
240 sg:person.01040055605.46 schema:affiliation grid-institutes:grid.47100.32
241 schema:familyName Klemen
242 schema:givenName Nicholas D.
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040055605.46
244 rdf:type schema:Person
245 sg:person.01076636275.12 schema:affiliation grid-institutes:grid.47100.32
246 schema:familyName Clune
247 schema:givenName James
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01076636275.12
249 rdf:type schema:Person
250 sg:person.01117026632.29 schema:affiliation grid-institutes:grid.47100.32
251 schema:familyName Cha
252 schema:givenName Charles
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117026632.29
254 rdf:type schema:Person
255 sg:person.01127457063.99 schema:affiliation grid-institutes:grid.47100.32
256 schema:familyName Olino
257 schema:givenName Kelly
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127457063.99
259 rdf:type schema:Person
260 sg:person.01156030507.16 schema:affiliation grid-institutes:grid.47100.32
261 schema:familyName Detterbeck
262 schema:givenName Frank C.
263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156030507.16
264 rdf:type schema:Person
265 sg:person.01166771111.54 schema:affiliation grid-institutes:grid.47100.32
266 schema:familyName Feingold
267 schema:givenName Paul L.
268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166771111.54
269 rdf:type schema:Person
270 sg:person.012276320555.98 schema:affiliation grid-institutes:grid.47100.32
271 schema:familyName Weiss
272 schema:givenName Sarah A.
273 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012276320555.98
274 rdf:type schema:Person
275 sg:person.012613314147.62 schema:affiliation grid-institutes:grid.47100.32
276 schema:familyName Khan
277 schema:givenName Sajid A.
278 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012613314147.62
279 rdf:type schema:Person
280 sg:person.01317277074.82 schema:affiliation grid-institutes:grid.416912.9
281 schema:familyName Pavri
282 schema:givenName Sabrina N.
283 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317277074.82
284 rdf:type schema:Person
285 sg:person.01336750727.45 schema:affiliation grid-institutes:grid.47100.32
286 schema:familyName Kluger
287 schema:givenName Harriet M.
288 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336750727.45
289 rdf:type schema:Person
290 sg:person.014265505777.28 schema:affiliation grid-institutes:grid.47100.32
291 schema:familyName Ariyan
292 schema:givenName Stephan
293 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014265505777.28
294 rdf:type schema:Person
295 sg:person.014455567337.71 schema:affiliation grid-institutes:grid.47100.32
296 schema:familyName Wang
297 schema:givenName Melinda
298 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014455567337.71
299 rdf:type schema:Person
300 sg:person.0607026044.65 schema:affiliation grid-institutes:grid.5288.7
301 schema:familyName Han
302 schema:givenName Dale
303 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607026044.65
304 rdf:type schema:Person
305 sg:person.0616726362.23 schema:affiliation grid-institutes:grid.47100.32
306 schema:familyName Salem
307 schema:givenName Ronald R.
308 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0616726362.23
309 rdf:type schema:Person
310 sg:person.0706626451.72 schema:affiliation grid-institutes:grid.47100.32
311 schema:familyName Sznol
312 schema:givenName Mario
313 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706626451.72
314 rdf:type schema:Person
315 sg:pub.10.1038/ng.2359 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021618497
316 https://doi.org/10.1038/ng.2359
317 rdf:type schema:CreativeWork
318 sg:pub.10.1245/s10434-012-2398-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1036889506
319 https://doi.org/10.1245/s10434-012-2398-z
320 rdf:type schema:CreativeWork
321 sg:pub.10.1245/s10434-013-2999-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013136445
322 https://doi.org/10.1245/s10434-013-2999-1
323 rdf:type schema:CreativeWork
324 sg:pub.10.1245/s10434-013-3089-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049896977
325 https://doi.org/10.1245/s10434-013-3089-0
326 rdf:type schema:CreativeWork
327 sg:pub.10.1245/s10434-016-5537-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026233646
328 https://doi.org/10.1245/s10434-016-5537-0
329 rdf:type schema:CreativeWork
330 sg:pub.10.1245/s10434-017-6072-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092156332
331 https://doi.org/10.1245/s10434-017-6072-3
332 rdf:type schema:CreativeWork
333 grid-institutes:grid.416912.9 schema:alternateName Orlando Health Aesthetic and Reconstructive Surgery Institute, Orlando, FL, USA
334 schema:name Orlando Health Aesthetic and Reconstructive Surgery Institute, Orlando, FL, USA
335 rdf:type schema:Organization
336 grid-institutes:grid.47100.32 schema:alternateName Department of Radiology, Yale School of Medicine, New Haven, CT, USA
337 Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA
338 Section of Plastic and Reconstructive Surgery, Yale School of Medicine, New Haven, CT, USA
339 Section of Surgical Oncology, Yale School of Medicine, 20 Park Street, 06519, New Haven, CT, USA
340 Section of Thoracic Surgery, Yale School of Medicine, New Haven, CT, USA
341 schema:name Department of Radiology, Yale School of Medicine, New Haven, CT, USA
342 Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA
343 Section of Plastic and Reconstructive Surgery, Yale School of Medicine, New Haven, CT, USA
344 Section of Surgical Oncology, Yale School of Medicine, 20 Park Street, 06519, New Haven, CT, USA
345 Section of Thoracic Surgery, Yale School of Medicine, New Haven, CT, USA
346 rdf:type schema:Organization
347 grid-institutes:grid.5288.7 schema:alternateName Division of Surgical Oncology, Oregon Health and Science University, Portland, OR, USA
348 schema:name Division of Surgical Oncology, Oregon Health and Science University, Portland, OR, USA
349 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...